Amedica spinal implant cleared
This article was originally published in The Gray Sheet
Executive Summary
Firm debuts the first ceramic spinal implants following 510(k) clearance of its Arx ceramic spinal spacer system, announced March 1. The Arx system is designed to replace collapsed or damaged vertebral bodies in the thoracolumbar region of the spine. Based on Amedica's MC2 technology, the ceramic replacements offer strength and the ability to bind with bone without the interference during diagnostic imaging that titanium implants can cause, the firm says. The market for spinal spacers is estimated to exceed $600 mil. annually...
You may also be interested in...
Financings In Brief
TransMedics: Funds totaling $29.75 mil. raised in a recent Series C financing led by 3i Group will be used to support expanded clinical trials for TransMedics' Organ Care System. The organ transport system is designed to optimize organ health and increase the number of usable transplant organs by maintaining the tissue in a warm, functioning state outside of the body. The firm anticipates European approval for the system for heart transplants in early 2007 following the completion of its PROTECT trial in the UK. Thanks to the funds raised, TransMedics plans to initiate trials in the U.S. and Europe and to extend its platform for use with additional organs such as the lungs, liver and kidneys...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.